SCHEMBL4938548

SCHEMBL4938548

CCn1c(SC(C)N2C=C(c3cccc(Cl)c3)ON2)nnc1-c1ccnc(OC)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.40
MAPT P10636 3/20 0.35
HTT P42858 3/20 0.35
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ALDH1A1 P00352 3/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
POLB P06746 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2C19 P33261 2/20 0.34
APOBEC3G Q9HC16 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
LMNA P02545 3/20 0.33
MAPK1 P28482 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1544595 0.78 KCNH2 (0.46) TSHRMAPTHTTCRHBPCRHR2
Pyridine SCHEMBL1545165 0.75 KCNH2 (0.47) TSHRMAPTHTTCRHBPCRHR2
SCHEMBL6320703 0.72 TSHR (0.44) TSHRMAPTHTTCRHBPCRHR2
SCHEMBL4946036 0.70 LMNA (0.35) TSHRMAPTHTTNPSR1ALDH1A1
SCHEMBL4946042 0.68 MAPT (0.45) TSHRMAPTHTTNPSR1ALDH1A1
SCHEMBL1544277 0.67 KCNH2 (0.42) TSHRMAPTALDH1A1MEN1KMT2A
SCHEMBL1543716 0.67 KCNH2 (0.46) TSHRMAPTHTTCRHBPCRHR2
SCHEMBL1544162 0.65 KCNH2 (0.44) TSHRMAPTHTTALDH1A1MEN1
SCHEMBL1544403 0.65 KCNH2 (0.57) TSHRMAPTALDH1A1MEN1KMT2A
SCHEMBL1544252 0.64 TSHR (0.43) TSHRMAPTHTTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045571-A1 ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045571-A1 ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS GRM5, GRIK5, GRM2 TSHR 895/4885MAPT 780/4885HTT 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.